Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist.

Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Heike S, Klaus B, Ambery PD, Meier JJ, Hirshberg B.

J Clin Endocrinol Metab. 2019 Oct 14. pii: dgz047. doi: 10.1210/clinem/dgz047. [Epub ahead of print]

PMID:
31608926
2.

Assessment of mixture toxicity of (tri)azoles and their hepatotoxic effects in vitro by means of omics technologies.

Seeger B, Mentz A, Knebel C, Schmidt F, Bednarz H, Niehaus K, Albaum S, Kalinowski J, Noll T, Steinberg P, Marx-Stoelting P, Heise T.

Arch Toxicol. 2019 Aug;93(8):2321-2333. doi: 10.1007/s00204-019-02502-w. Epub 2019 Jun 28.

PMID:
31254001
3.

The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects.

Halberg IB, Lyby K, Wassermann K, Heise T, Plum-Mörschel L, Zijlstra E.

Clin Pharmacokinet. 2019 May 16. doi: 10.1007/s40262-019-00772-2. [Epub ahead of print]

PMID:
31093929
4.

Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes.

Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Mégret C, Gaudier M, Soula O, Plum-Mörschel L.

Diabetes Obes Metab. 2019 Jul;21(7):1570-1575. doi: 10.1111/dom.13685. Epub 2019 Apr 8.

PMID:
30828929
5.

Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.

Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.

Lancet Diabetes Endocrinol. 2019 Mar;7(3):179-188. doi: 10.1016/S2213-8587(18)30372-3. Epub 2019 Jan 21.

PMID:
30679095
6.

Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.

van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, Heise T, van Scherpenzeel M, Lefeber DJ, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ.

J Biol Chem. 2019 Mar 22;294(12):4437-4449. doi: 10.1074/jbc.RA118.002763. Epub 2019 Jan 22.

PMID:
30670592
7.

Comparison of three meta-analytic methods using data from digital interventions on type 2 diabetes.

Kebede MM, Peters M, Heise TL, Pischke CR.

Diabetes Metab Syndr Obes. 2018 Dec 19;12:59-73. doi: 10.2147/DMSO.S180106. eCollection 2019.

8.

Concentrated insulins in current clinical practice.

Schloot NC, Hood RC, Corrigan SM, Panek RL, Heise T.

Diabetes Res Clin Pract. 2019 Feb;148:93-101. doi: 10.1016/j.diabres.2018.12.007. Epub 2018 Dec 21. Review.

9.

BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.

Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode B.

Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13621. [Epub ahead of print]

PMID:
30565407
10.

Potent Metabolic Sialylation Inhibitors Based on C-5-Modified Fluorinated Sialic Acids.

Heise T, Pijnenborg JFA, Büll C, van Hilten N, Kers-Rebel ED, Balneger N, Elferink H, Adema GJ, Boltje TJ.

J Med Chem. 2019 Jan 24;62(2):1014-1021. doi: 10.1021/acs.jmedchem.8b01757. Epub 2018 Dec 31.

11.

In vitro proteomic analysis of methapyrilene toxicity in rat hepatocytes reveals effects on intermediary metabolism.

Braeuning A, Oberemm A, Heise T, Gundert-Remy U, Hengstler JG, Lampen A.

Arch Toxicol. 2019 Feb;93(2):369-383. doi: 10.1007/s00204-018-2360-3. Epub 2018 Nov 22.

PMID:
30467583
12.

The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway.

Knebel C, Heise T, Zanger UM, Lampen A, Marx-Stoelting P, Braeuning A.

Food Chem Toxicol. 2019 Jan;123:481-491. doi: 10.1016/j.fct.2018.11.039. Epub 2018 Nov 17.

PMID:
30458266
13.

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.

Haahr H, Pieber TR, Mathieu C, Gondolf T, Shiramoto M, Erichsen L, Heise T.

Clin Pharmacokinet. 2019 May;58(5):639-649. doi: 10.1007/s40262-018-0718-6.

14.

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.

Hövelmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T.

Diabetes Obes Metab. 2019 Mar;21(3):601-610. doi: 10.1111/dom.13562. Epub 2018 Nov 28.

15.

Voluntary industry initiatives to promote healthy diets: a case study on a major European food retailer.

von Philipsborn P, Stratil JM, Heise TL, Landgraf R, Hauner H, Rehfuess EA.

Public Health Nutr. 2018 Dec;21(18):3469-3476. doi: 10.1017/S1368980018002744. Epub 2018 Oct 18.

PMID:
30334511
16.

Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.

Al-Qaissi A, Papageorgiou M, Javed Z, Heise T, Rigby AS, Garrett AT, Hepburn D, Kilpatrick ES, Atkin SL, Sathyapalan T.

Diabetes Obes Metab. 2019 Mar;21(3):569-574. doi: 10.1111/dom.13555. Epub 2018 Nov 4.

PMID:
30311402
17.

Propiconazole is an activator of AHR and causes concentration additive effects with an established AHR ligand.

Knebel C, Kebben J, Eberini I, Palazzolo L, Hammer HS, Süssmuth RD, Heise T, Hessel-Pras S, Lampen A, Braeuning A, Marx-Stoelting P.

Arch Toxicol. 2018 Dec;92(12):3471-3486. doi: 10.1007/s00204-018-2321-x. Epub 2018 Oct 6.

18.

Effectiveness of Digital Interventions for Improving Glycemic Control in Persons with Poorly Controlled Type 2 Diabetes: A Systematic Review, Meta-analysis, and Meta-regression Analysis.

Kebede MM, Zeeb H, Peters M, Heise TL, Pischke CR.

Diabetes Technol Ther. 2018 Nov;20(11):767-782. doi: 10.1089/dia.2018.0216. Epub 2018 Sep 26.

PMID:
30257102
19.

Considering Blood Dilution improves the Precision of Continuous Whole Blood Glucose Measurements.

Benesch C, Kuhlenkötter M, Heise T.

J Diabetes Sci Technol. 2019 Jul;13(4):751-755. doi: 10.1177/1932296818803621. Epub 2018 Sep 26.

20.

Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project.

Schliess F, Heise T, Benesch C, Mianowska B, Stegbauer C, Broge B, Gillard P, Binkley G, Crône V, Carlier S, Delval C, Petkov A, Beck JP, Lodwig V, Gurdala M, Szecsenyi J, Rosenmöller M, Cypryk K, Mathieu C, Renard E, Heinemann L.

J Diabetes Sci Technol. 2019 Mar;13(2):261-267. doi: 10.1177/1932296818803588. Epub 2018 Sep 21.

21.

Selective Inhibition of Sialic Acid-Based Molecular Mimicry in Haemophilus influenzae Abrogates Serum Resistance.

Heise T, Langereis JD, Rossing E, de Jonge MI, Adema GJ, Büll C, Boltje TJ.

Cell Chem Biol. 2018 Oct 18;25(10):1279-1285.e8. doi: 10.1016/j.chembiol.2018.05.018. Epub 2018 Jul 5.

PMID:
29983272
22.

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.

Lancet. 2018 Jun 30;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8. Epub 2018 Jun 23.

PMID:
29945727
23.

Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.

Andersen G, Meiffren G, Lamers D, DeVries JH, Ranson A, Seroussi C, Alluis B, Gaudier M, Soula O, Heise T.

Diabetes Obes Metab. 2018 Nov;20(11):2627-2632. doi: 10.1111/dom.13442. Epub 2018 Jul 12.

PMID:
29923294
24.

Abbreviated literature searches were viable alternatives to comprehensive searches: a meta-epidemiological study.

Nussbaumer-Streit B, Klerings I, Wagner G, Heise TL, Dobrescu AI, Armijo-Olivo S, Stratil JM, Persad E, Lhachimi SK, Van Noord MG, Mittermayr T, Zeeb H, Hemkens L, Gartlehner G.

J Clin Epidemiol. 2018 Oct;102:1-11. doi: 10.1016/j.jclinepi.2018.05.022. Epub 2018 Jun 2.

PMID:
29864540
25.

Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?

Heise T, Heckermann S, Hans DeVries J.

Diabetes Obes Metab. 2018 Sep;20(9):2051-2056. doi: 10.1111/dom.13365. Epub 2018 Jun 10. No abstract available.

PMID:
29770552
26.

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.

Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.

Horm Metab Res. 2018 May;50(5):403-407. doi: 10.1055/a-0591-9442. Epub 2018 May 4.

PMID:
29727906
27.

Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity.

Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ.

Cancer Res. 2018 Jul 1;78(13):3574-3588. doi: 10.1158/0008-5472.CAN-17-3376. Epub 2018 Apr 27.

28.

Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes.

Moser O, Eckstein ML, McCarthy O, Deere R, Bain SC, Haahr HL, Zijlstra E, Heise T, Bracken RM.

PLoS One. 2018 Apr 2;13(4):e0194750. doi: 10.1371/journal.pone.0194750. eCollection 2018.

29.

A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3).

Ólafsdóttir AF, Polonsky W, Bolinder J, Hirsch IB, Dahlqvist S, Wedel H, Nyström T, Wijkman M, Schwarcz E, Hellman J, Heise T, Lind M.

Diabetes Technol Ther. 2018 Apr;20(4):274-284. doi: 10.1089/dia.2017.0363. Epub 2018 Apr 2.

30.

The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.

Stinkens R, van der Kolk BW, Jordan J, Jax T, Engeli S, Heise T, Jocken JW, May M, Schindler C, Havekes B, Schaper N, Albrecht D, Kaiser S, Hartmann N, Letzkus M, Langenickel TH, Goossens GH, Blaak EE.

Sci Rep. 2018 Mar 2;8(1):3933. doi: 10.1038/s41598-018-22194-z.

31.

Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.

Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T.

Diabetes Obes Metab. 2018 May;20(5):1140-1147. doi: 10.1111/dom.13203. Epub 2018 Jan 25.

32.

Mixture effects of two plant protection products in liver cell lines.

Zahn E, Wolfrum J, Knebel C, Heise T, Weiß F, Poetz O, Marx-Stoelting P, Rieke S.

Food Chem Toxicol. 2018 Feb;112:299-309. doi: 10.1016/j.fct.2017.12.067. Epub 2017 Dec 30.

33.

Naswar (Smokeless Tobacco) Use and the Risk of Oral Cancer in Pakistan: A Systematic Review With Meta-Analysis.

Khan Z, Suliankatchi RA, Heise TL, Dreger S.

Nicotine Tob Res. 2019 Jan 1;21(1):32-40. doi: 10.1093/ntr/ntx281.

PMID:
29294113
34.

External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review.

Ogurtsova K, Heise TL, Linnenkamp U, Dintsios CM, Lhachimi SK, Icks A.

Syst Rev. 2017 Dec 29;6(1):267. doi: 10.1186/s13643-017-0664-7.

35.

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Møller DV, Heise T.

Diabetes Care. 2018 Mar;41(3):531-537. doi: 10.2337/dc17-1402. Epub 2017 Dec 22.

PMID:
29273578
36.

Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.

Engeli S, Stinkens R, Heise T, May M, Goossens GH, Blaak EE, Havekes B, Jax T, Albrecht D, Pal P, Tegtbur U, Haufe S, Langenickel TH, Jordan J.

Hypertension. 2018 Jan;71(1):70-77. doi: 10.1161/HYPERTENSIONAHA.117.10224. Epub 2017 Nov 27.

37.

SUMO Modification of the RNA-Binding Protein La Regulates Cell Proliferation and STAT3 Protein Stability.

Kota V, Sommer G, Hazard ES, Hardiman G, Twiss JL, Heise T.

Mol Cell Biol. 2017 Dec 29;38(2). pii: e00129-17. doi: 10.1128/MCB.00129-17. Print 2018 Jan 15.

39.

Hepatotoxic combination effects of three azole fungicides in a broad dose range.

Heise T, Schmidt F, Knebel C, Rieke S, Haider W, Geburek I, Niemann L, Marx-Stoelting P.

Arch Toxicol. 2018 Feb;92(2):859-872. doi: 10.1007/s00204-017-2087-6. Epub 2017 Oct 16.

40.

Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.

Heise T, Kaplan K, Haahr HL.

J Diabetes Sci Technol. 2018 Mar;12(2):356-363. doi: 10.1177/1932296817731422. Epub 2017 Sep 26.

41.

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.

Zijlstra E, Demissie M, Graungaard T, Heise T, Nosek L, Bode B.

J Diabetes Sci Technol. 2018 Jan;12(1):145-151. doi: 10.1177/1932296817730375. Epub 2017 Sep 18.

42.

Axonal localization of neuritin/CPG15 mRNA is limited by competition for HuD binding.

Gomes C, Lee SJ, Gardiner AS, Smith T, Sahoo PK, Patel P, Thames E, Rodriguez R, Taylor R, Yoo S, Heise T, Kar AN, Perrone-Bizzozero N, Twiss JL.

J Cell Sci. 2017 Nov 1;130(21):3650-3662. doi: 10.1242/jcs.201244. Epub 2017 Sep 4.

43.

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8.

Harris C, Forst T, Heise T, Plum-Mörschel L, Watkins E, Zhang Q, Fan L, Garhyan P, Porksen N.

Diabetes Technol Ther. 2017 Aug;19(8):463-470. doi: 10.1089/dia.2016.0414.

44.

Use of endpoint adjudication to improve the quality and validity of endpoint assessment for medical device development and post marketing evaluation: Rationale and best practices. A report from the cardiac safety research consortium.

Seltzer JH, Heise T, Carson P, Canos D, Hiatt JC, Vranckx P, Christen T, Cutlip DE.

Am Heart J. 2017 Aug;190:76-85. doi: 10.1016/j.ahj.2017.05.009. Epub 2017 May 28. Review.

PMID:
28760216
45.

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.

Jordan J, Tank J, Heusser K, Heise T, Wanner C, Heer M, Macha S, Mattheus M, Lund SS, Woerle HJ, Broedl UC.

J Am Soc Hypertens. 2017 Sep;11(9):604-612. doi: 10.1016/j.jash.2017.07.005. Epub 2017 Jul 21.

PMID:
28757109
46.

Metabolic Oligosaccharide Engineering with Alkyne Sialic Acids Confers Neuraminidase Resistance and Inhibits Influenza Reproduction.

Heise T, Büll C, Beurskens DM, Rossing E, de Jonge MI, Adema GJ, Boltje TJ, Langereis JD.

Bioconjug Chem. 2017 Jul 19;28(7):1811-1815. doi: 10.1021/acs.bioconjchem.7b00224. Epub 2017 Jun 27.

47.

Community gardening, community farming and other local community-based gardening interventions to prevent overweight and obesity in high-income and middle-income countries: protocol for a systematic review.

Heise TL, Romppel M, Molnar S, Buchberger B, Berg AVD, Gartlehner G, Lhachimi SK.

BMJ Open. 2017 Jun 15;7(6):e016237. doi: 10.1136/bmjopen-2017-016237.

48.

Introduction of biosimilar insulins in Europe.

Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C.

Diabet Med. 2017 Oct;34(10):1340-1353. doi: 10.1111/dme.13400. Epub 2017 Jul 16. Review.

49.

Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas.

Heise T, Hövelmann U, Nosek L, Sassenfeld B, Thomsen KMD, Haahr H.

Clin Drug Investig. 2017 Sep;37(9):885-887. doi: 10.1007/s40261-017-0539-7. No abstract available.

PMID:
28597216
50.

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.

Goldman J, Kapitza C, Pettus J, Heise T.

Curr Med Res Opin. 2017 Oct;33(10):1821-1831. doi: 10.1080/03007995.2017.1335192. Epub 2017 Jun 23. Review.

PMID:
28537449

Supplemental Content

Support Center